Download App

Log in to access Online Inquiry
Company Overview More
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma. Its product pipeline includes MOR208, an antibody for the treatment of haematological cancers; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; MOR106, an antibody for rheumatoid arthritis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macao; a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs; and a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys' investigational compound tafasitamab (MOR208). The company was founded in 1992 and is headquartered in Planegg, Germany.
CEO: Kress, Jean-Paul
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

MOR MorphoSys
5.240+0.180+3.56%
Post Mkt Price
5.24000.00%
YOY
Do not show
Hide blank lines
(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30(Q2)2021/06/30
Assets
Current assets
Cash, cash equivalents and short term investments
-8.86% 993.66M -8.86% 993.66M 46.32% 1.16B 27.35% 1.1B
-Cash and cash equivalents
12.25% 123.25M 12.25% 123.25M 288.36% 249.77M 790.11% 297.33M
-Short-term investments
-11.23% 870.42M -11.23% 870.42M 24.85% 905.43M -3.47% 798.01M
Receivables
-4.5% 85.79M -4.5% 85.79M 105.55% 82.07M 195.14% 108.19M
-Accounts receivable
-8.93% 75.91M -8.93% 75.91M 144.1% 77.04M 193.53% 97.17M
-Taxes receivable
77.06% 7.65M 77.06% 7.65M 59.3% 587.9K 203.7% 504.36K
-Other receivables
3.12% 2.23M 3.12% 2.23M -44.51% 4.44M 210.45% 10.52M
Inventory
108.33% 20.76M 108.33% 20.76M -12.91% 13.27M -5.3% 14.52M
Prepaid assets
151.05% 16.82M 151.05% 16.82M 221.14% 44.23M 139.38% 37.85M
Other current assets
59.4% 15.94M 59.4% 15.94M -- -- -- --
Total current assets
-6.12% 1.13B -6.12% 1.13B 50.83% 1.29B 35.35% 1.26B
Non current assets
Net PPE
-2.27% 49.59M -2.27% 49.59M -0.37% 51.92M -4.16% 49.42M
-Gross PPE
2.13% 69.86M 2.13% 69.86M -0.37% 51.92M -4.16% 49.42M
-Accumulated depreciation
-14.78% -20.27M -14.78% -20.27M -- -- -- --
Goodwill and other intangible assets
1553.49% 1.17B 1553.49% 1.17B 2075.96% 1.36B 92.32% 80.64M
-Goodwill
20627.24% 335.57M 20627.24% 335.57M 15431.08% 570.96M -55.95% 1.62M
-Other intangible assets
1108.37% 838.32M 1108.37% 838.32M 1240.6% 787.91M 106.57% 79.03M
Investments and advances
-- 0 -- 0 -- 0 -78.41% 55.38M
Non current deferred assets
40.46% 186.55M 40.46% 186.55M 9.74% 165.41M -7.46% 134.29M
Non current prepaid assets
4922.95% 9.19M 4922.95% 9.19M 720.37% 12.99M 59.88% 1.77M
Other non current assets
193.46% 4.06M 193.46% 4.06M -- -- -- --
Total non current assets
214.4% 1.42B 214.4% 1.42B 204.61% 1.59B -35.2% 321.51M
Total assets
54.04% 2.56B 54.04% 2.56B 108.96% 2.88B 10.77% 1.58B
Liabilities
Current liabilities
Payables
54.31% 73.79M 54.31% 73.79M -- -- -- --
-accounts payable
55.15% 73.79M 55.15% 73.79M -- -- -- --
Current accrued expenses
41.56% 114.29M 41.56% 114.29M -- -- -- --
Current provisions
-- 2.55M -- 2.55M 1385.53% 4.12M 20.38% 658.15K
Current debt and capital lease obligation
5.25% 3.66M 5.25% 3.66M 29.99% 4.09M 18.01% 3.68M
-Current debt
0% 422.95K 0% 422.95K -- 929.37K -- 417.28K
-Current capital lease obligation
5.97% 3.24M 5.97% 3.24M 0.47% 3.16M 4.64% 3.26M
Current deferred liabilities
-98.9% 752.08K -98.9% 752.08K -31.06% 64.13M -42.41% 65.55M
Other current liabilities
57604.71% 89.5M 57604.71% 89.5M -- 18.38M -- --
Current liabilities
41.94% 284.54M 41.94% 284.54M 51.64% 259.12M 19.19% 204.55M
Non current liabilities
Long term provisions
3.18% 1.58M 3.18% 1.58M 21.95% 1.52M 233.49% 2.22M
Long term debt and capital lease obligation
2.35% 322.13M 2.35% 322.13M 644.55% 320.18M 623.48% 318.27M
-Long term debt
3.68% 282.78M 3.68% 282.78M -- 280.22M -- 277.68M
-Long term capital lease obligation
-6.24% 39.35M -6.24% 39.35M -7.06% 39.97M -7.72% 40.59M
Non current deferred liabilities
330.74% 22.09M 330.74% 22.09M 255.33% 23.9M -61.06% 5.11M
Derivative product liabilities
-- -- -- -- -- 1.19B -- --
Other non current liabilities
225.56% 1.68B 225.56% 1.68B -12.62% 489.56M -17.16% 445.86M
Total non current liabilities
141.94% 2.03B 141.94% 2.03B 231.72% 2.03B 29.44% 771.45M
Total liabilities
122.64% 2.31B 122.64% 2.31B 192.38% 2.29B 27.15% 976.01M
Shareholders'equity
Share capital
4.08% 34.23M 4.08% 34.23M 4.08% 34.23M 0.01% 32.89M
-common stock
4.08% 34.23M 4.08% 34.23M 4.08% 34.23M 0.01% 32.89M
Retained earnings
-325.84% -672.35M -325.84% -672.35M -106.12% -291.38M -134.95% -178.6M
Paid-in capital
11.26% 833.32M 11.26% 833.32M 17.02% 832.58M 5.49% 749.28M
Less: Treasury stock
-36.64% 3.09M -36.64% 3.09M -39.59% 3.37M -40.74% 3.78M
Gains losses not affecting retained earnings
2285.69% 52.76M 2285.69% 52.76M 4104.77% 25.18M 137.77% 1.62M
Total stockholders'equity
-60.59% 244.88M -60.59% 244.88M -0.13% 597.25M -8.39% 601.41M
Total equity
-60.59% 244.88M -60.59% 244.88M -0.13% 597.25M -8.39% 601.41M
Currency Unit
EUREUREUREUR
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
Unqualified Opinion------

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%